[The 43rd Report on the Survey of Adverse Reactions to Radiopharmaceuticals (46th Survey in 2020)].

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2022-01-01 DOI:10.18893/kakuigaku.rp.2231

Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura

引用次数: 0

Abstract

This survey was performed to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2020 in Japan. The results are based on responses to questionnaires sent to nuclear medicine centers. Replies were obtained from 1,006 centers out of 1,212 to which the questionnaire was sent. A total of 940,758 administrations of radiopharmaceuticals were reported. There were 17 cases with adverse reactions, giving an incidence of adverse reactions of 1.8 per 100,000 cases. Two cases of defective products were reported, giving an incidence of defective products of 0.2 per 100,000 cases.

查看原文本刊更多论文

[第43次放射性药品不良反应调查报告(2020年第46次调查)]。

本调查旨在调查2020财年日本放射性药物不良反应的发生率。这些结果是基于对核医学中心的问卷调查。在收到问卷的1,212个中心中，有1,006个中心给出了答复。共报告了940,758次放射性药物用药。不良反应17例，不良反应发生率为1.8 / 10万例。报告了两例次品，次品发生率为每10万例0.2例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kaku igaku. The Japanese journal of nuclear medicine Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The main scope of JSNM is the appropriate development of the application of radioactive substances and stable nuclides in medicine. Towards this scope, JSNM promotes the exchange of idea and information, and researches in nuclear medicine. JSNM are interested in the international collaboration for the development of nuclear medicine. Through the activities, JSNM contributes to the medicine, as well as humanity, not only in Japan but also in any countries over the world.